NYSE:PBH

Stock Analysis Report

Executive Summary

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in North America, Australia, and internationally.

Snowflake

Fundamentals

Slightly overvalued with imperfect balance sheet.


Similar Companies

Share Price & News

How has Prestige Consumer Healthcare's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.2%

PBH

-0.1%

US Pharmaceuticals

1.0%

US Market


1 Year Return

-8.5%

PBH

-6.2%

US Pharmaceuticals

6.7%

US Market

Return vs Industry: PBH underperformed the US Pharmaceuticals industry which returned -6.2% over the past year.

Return vs Market: PBH underperformed the US Market which returned 6.7% over the past year.


Share holder returns

PBHIndustryMarket
7 Day-1.2%-0.1%1.0%
30 Day-1.9%-0.5%-1.8%
90 Day14.2%-2.6%-1.8%
1 Year-8.5%-8.5%-3.9%-6.2%9.1%6.7%
3 Year-24.9%-24.9%17.4%9.1%46.1%36.6%
5 Year11.9%11.9%28.0%14.5%66.9%48.6%

Price Volatility Vs. Market

How volatile is Prestige Consumer Healthcare's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Prestige Consumer Healthcare undervalued based on future cash flows and its price relative to the stock market?

36%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Undervalued: PBH ($35.3) is trading below our estimate of fair value ($55.12)

Significantly Undervalued: PBH is trading below fair value, but not by a significant amount.


Price Based on Earnings

PE vs Industry: PBH is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: PBH is unprofitable, so we can't compare its PE Ratio to the US market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate PBH's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: PBH is good value based on its PB Ratio (1.6x) compared to the US Pharmaceuticals industry average (2.8x).


Next Steps

Future Growth

How is Prestige Consumer Healthcare expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

59.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: PBH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PBH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PBH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PBH's revenue (0.8% per year) is forecast to grow slower than the US market (7.3% per year).

High Growth Revenue: PBH's revenue (0.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if PBH's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Prestige Consumer Healthcare performed over the past 5 years?

15.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: PBH is unprofitable, but has reduced losses over the past 5 years at a rate of 15.6% per year.

Accelerating Growth: Unable to compare PBH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PBH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (24.3%).


Return on Equity

High ROE: PBH has a negative Return on Equity (-3.3%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: PBH is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: PBH is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Prestige Consumer Healthcare's financial position?


Financial Position Analysis

Short Term Liabilities: PBH's short term assets ($310.5M) exceeds its short term liabilities ($143.5M)

Long Term Liabilities: PBH's short term assets (310.5M) do not cover its long term liabilities (2.2B)


Debt to Equity History and Analysis

Debt Level: PBH's debt to equity ratio (161.5%) is considered high

Reducing Debt: PBH's debt to equity ratio has reduced from 166.8% to 161.5% over the past 5 years.

Debt Coverage: PBH's debt is not well covered by operating cash flow (10.5%).

Interest Coverage: PBH is unprofitable, therefore interest payments are not well covered by earnings.


Balance Sheet

Inventory Level: PBH has a low level of unsold assets or inventory.

Debt Coverage by Assets: PBH's debt is not covered by short term assets (assets are 0.2x debt).


Next Steps

Dividend

What is Prestige Consumer Healthcare's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.3%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate PBH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PBH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if PBH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PBH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PBH's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Prestige Consumer Healthcare's salary, the management and board of directors tenure and is there insider trading?

2.9yrs

Average management tenure


CEO

Ron Lombardi (55yo)

4.3yrs

Tenure

US$4,274,547

Compensation

Mr. Ronald M. Lombardi, also known as Ron, has been the Chief Executive Officer and President of Prestige Brands Holdings, Inc. (now Prestige Consumer Healthcare Inc.) since June 2015 and has been its Chai ...


CEO Compensation Analysis

Compensation vs. Market: Ron's total compensation ($USD4.27M) is about average for companies of similar size in the US market ($USD4.08M).

Compensation vs Earnings: Ron's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.9yrs

Average Tenure

54.5yo

Average Age

Experienced Management: PBH's management team is considered experienced (2.9 years average tenure).


Board Age and Tenure

4.2yrs

Average Tenure

67yo

Average Age

Experienced Board: PBH's board of directors are considered experienced (4.2 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$1,300,50020 Nov 18
Timothy Connors
EntityIndividual
Shares34,000
Max PriceUS$38.25
SellUS$557,70015 Nov 18
Timothy Connors
EntityIndividual
Shares14,300
Max PriceUS$39.00

Ownership Breakdown


Management Team

  • Chris Sacco (43yo)

    Chief Financial Officer

    • Tenure: 3.1yrs
    • Compensation: US$1.54m
  • Phil Terpolilli

    Director of Investor Relations

    • Tenure: 0yrs
  • Bill P'Pool (54yo)

    Senior VP

    • Tenure: 2.9yrs
    • Compensation: US$1.05m
  • Dean Siegal

    Director of Communications

    • Tenure: 0yrs
  • Ron Lombardi (55yo)

    Chairman

    • Tenure: 4.3yrs
    • Compensation: US$4.27m
  • Jeff Zerillo (58yo)

    Senior Vice President of Operations

    • Tenure: 1.5yrs
    • Compensation: US$1.01m
  • Mary Fritz

    Senior Vice President of Quality & Regulatory Affairs

    • Tenure: 1.3yrs

Board Members

  • Gary Costley (75yo)

    Lead Independent Director

    • Tenure: 10.1yrs
    • Compensation: US$235.02k
  • John Byom (65yo)

    Independent Director

    • Tenure: 13.8yrs
    • Compensation: US$227.52k
  • Jim Jenness (73yo)

    Independent Director

    • Tenure: 4.4yrs
    • Compensation: US$225.02k
  • Nat Ricciardi (70yo)

    Independent Director

    • Tenure: 3.4yrs
    • Compensation: US$210.02k
  • Chris Coughlin (67yo)

    Independent Director

    • Tenure: 0.3yrs
  • Sheila Hopkins (63yo)

    Independent Director

    • Tenure: 4.2yrs
    • Compensation: US$210.02k
  • Ron Lombardi (55yo)

    Chairman

    • Tenure: 4.3yrs
    • Compensation: US$4.27m

Company Information

Prestige Consumer Healthcare Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Prestige Consumer Healthcare Inc.
  • Ticker: PBH
  • Exchange: NYSE
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.774b
  • Shares outstanding: 50.24m
  • Website: https://www.prestigebrands.com

Number of Employees


Location

  • Prestige Consumer Healthcare Inc.
  • 660 White Plains Road
  • Suite 250
  • Tarrytown
  • New York
  • 10591
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PBVDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2005
PBHNYSE (New York Stock Exchange)YesCommon StockUSUSDFeb 2005

Biography

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in North America, Australia, and intern ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 01:42
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)